San Diego-dependent Viking Therapeutics marked by itself as a significant competitor while in the weight loss drug industry in February after revealing promising details from the mid-phase demo of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when offered being a weekly injection As well as in March th